Platelets From a Patient Heterozygous for the Defect of P2 CYC Receptors for ADP Have a Secretion Defect Despite Normal Thromboxane A 2 Production and Normal Granule Stores
- 1 November 2000
- journal article
- other
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 20 (11) , E101-6
- https://doi.org/10.1161/01.atv.20.11.e101
Abstract
—Two unrelated patients with a congenital bleeding diathesis associated with a severe defect of the platelet ADP receptor coupled to adenylate cyclase (P2 CYC ) have been described so far. In one of them, platelet secretion was shown to be abnormal. We recently showed that platelets with the primary secretion defect (PSD; characterized by abnormal secretion but normal granule stores, thromboxane A 2 production, and ADP-induced primary wave of aggregation) have a moderate defect of P2 CYC . Therefore, the interaction of ADP with the full complement of its receptors seems to be essential for normal platelet secretion, and PSD patients may be heterozygotes for the congenital severe defect of P2 CYC . In this study, we describe 2 new related patients with a severe defect of P2 CYC and the son of one of them, who is to be considered an obligate heterozygote for the defect. The 2 patients with the severe defect had lifelong histories of abnormal bleeding, prolonged bleeding times, abnormalities of platelet aggregation and secretion, lack of inhibition of adenylate cyclase by ADP, and a deficiency of platelet-binding sites for [ 33 P]2 MeS-ADP (240 and 225 sites per platelet; normal range, 530 to 1102). The son of one of them had a mildly prolonged bleeding time and abnormalities of platelet aggregation and secretion similar to those found in patients with PSD. In addition, his platelets showed a moderate defect of binding sites for [ 33 P]2 MeS-ADP (430 sites per platelet) and of adenylate cyclase inhibition by ADP. This study of a family with the platelet disorder characterized by a defect of the platelet P2 CYC receptor supports our hypothesis that the full complement of the platelet ADP receptors is essential for normal platelet secretion and that some patients with the common, ill-defined diagnosis of PSD are actually heterozygous for the defect.Keywords
This publication has 27 references indexed in Scilit:
- Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y1 receptor–null miceJournal of Clinical Investigation, 1999
- Antagonists of the Platelet P2T Receptor: A Novel Approach to Antithrombotic TherapyJournal of Medicinal Chemistry, 1999
- Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptorsEuropean Journal of Pharmacology, 1998
- Hereditary defect of the platelet ADP receptor(s)Platelets, 1998
- Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptorsBritish Journal of Haematology, 1995
- An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function.Journal of Clinical Investigation, 1995
- Sustained correction of the bleeding time in an afibrinogenaemic patient after infusion of fresh frozen plasmaBritish Journal of Haematology, 1992
- The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1Biochemical Pharmacology, 1990
- LIGAND: A versatile computerized approach for characterization of ligand-binding systemsAnalytical Biochemistry, 1980
- THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONSAnnals of the New York Academy of Sciences, 1949